Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes

European Urology

Volumn 68, Issue 4, 2015, Pages 555-567

  Tomlins, Scott A ^a   Alshalalfa, Mohammed ^b   Davicioni, Elai ^b   Erho, Nicholas ^b   Yousefi, Kasra ^b   Zhao, Shuang ^a   Haddad, Zaid ^b   Den, Robert B ^c   Dicker, Adam P ^c   Trock, Bruce J ^d   Demarzo, Angelo M ^d   Ross, Ashley E ^d   Schaeffer, Edward M ^d   Klein, Eric A ^e   Magi Galluzzi, Cristina ^e   Karnes, R Jeffrey ^f   Jenkins, Robert B ^g   Feng, Felix Y ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b GenomeDx Bioscience Inc   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f DEPARTMENT OF UROLOGY   (United States)

^g MAYO CLINIC   (United States)

Author keywords

ERG; ETS; Microarray; Prognosis; Prostate cancer; SPINK1

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; CARRIER PROTEIN; ERG PROTEIN, HUMAN; SPINK1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TUMOR MARKER;

ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL CYCLE PROGRESSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLEASON SCORE; GOLD STANDARD; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MICROARRAY KIT; MOLECULAR DIAGNOSIS; MOLECULAR TYPING; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; RANDOM FOREST; SEMINAL VESICLE; AREA UNDER THE CURVE; CANCER GRADING; CLASSIFICATION; CLINICAL TRIAL; CLUSTER ANALYSIS; DNA MICROARRAY; EUROPE; GENE EXPRESSION REGULATION; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; STATISTICAL MODEL; UNITED STATES; UPREGULATION; VALIDATION STUDY;

AREA UNDER CURVE; BIOMARKERS, TUMOR; CARRIER PROTEINS; CLUSTER ANALYSIS; EUROPE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG; UNITED STATES; UP-REGULATION;

EID: 84941809215     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.04.033     Document Type: Article

References (46)

1. M.A. Svensson, C.J. LaFargue, T.Y. MacDonald, and et al. Testing mutual exclusivity of ETS rearranged prostate cancer Lab Invest 91 2011 404 412
2. M.A. Rubin, C.A. Maher, and A.M. Chinnaiyan Common gene rearrangements in prostate cancer J Clin Oncol 29 2011 3659 3668
3. M.A. Rubin ETS rearrangements in prostate cancer Asian J Androl 14 2012 393 399
4. C.E. Barbieri, and S.A. Tomlins The prostate cancer genome: perspectives and potential Urol Oncol Semin Orig Investig 32 2014 53.e15-22
5. S.A. Tomlins, D.R. Rhodes, J. Yu, and et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers Cancer Cell 13 2008 519 528
6. B. Furusato, S.-H. Tan, D. Young, and et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification Prostate Cancer Prostatic Dis 13 2010 228 237
7. L.P. Kunju, S. Carskadon, J. Siddiqui, S.A. Tomlins, A.M. Chinnaiyan, and N. Palanisamy Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer Appl Immunohistochem Mol Morphol 22 2014 e32 e40
8. J. Cuzick, G.P. Swanson, G. Fisher, and et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study Lancet Oncol 12 2011 245 255
9. N. Erho, A. Crisan, I.A. Vergara, and et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy PLoS One 8 2013 e66855
10. E.A. Klein, M.R. Cooperberg, C. Magi-Galluzzi, and et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling Eur Urol 66 2014 550 560
11. J. Davis Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact BJU Int 114 2014 320 322
12. R. Arora, M.O. Koch, J.N. Eble, T.M. Ulbright, L. Li, and L. Cheng Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate Cancer 100 2004 2362 2366
13. R. Mehra, B. Han, S.A. Tomlins, and et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases Cancer Res 67 2007 7991 7995
14. M. Barry, S. Perner, F. Demichelis, and M.A. Rubin TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications Urology 70 2007 630 633
15. S. Perner, F. Demichelis, R. Beroukhim, and et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer Cancer Res 66 2006 8337 8341
16. F. Demichelis, and M.A. Rubin TMPRSS2-ETS fusion prostate cancer: biological and clinical implications J Clin Pathol 60 2007 1185 1186
17. S.A. Tomlins, A. Bjartell, A.M. Chinnaiyan, and et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice Eur Urol 56 2009 275 286
18. S. Minner, M. Gärtner, F. Freudenthaler, and et al. Marked heterogeneity of ERG expression in large primary prostate cancers Mod Pathol 26 2013 106 116
19. M.C. Haffner, T. Mosbruger, D.M. Esopi, and et al. Tracking the clonal origin of lethal prostate cancer J Clin Invest 123 2013 4918 4922
20. M.C. Haffner, A.M. De Marzo, S. Yegnasubramanian, J.I. Epstein, and H.B. Carter Diagnostic Challenges of Clonal Heterogeneity in Prostate Cancer J Clin Oncol 32 2014 2013 2015
21. R.J. Karnes, E.J. Bergstralh, E. Davicioni, and et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population J Urol 190 2013 2047 2053
22. R.B. Den, F.Y. Feng, T.N. Showalter, and et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy Int J Radiat Oncol 89 2014 1038 1046
23. E.A. Klein, K. Yousefi, Z. Haddad, and et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy Eur Urol 67 2015 778 786
24. B.S. Taylor, N. Schultz, H. Hieronymus, and et al. Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
25. J.L. Boormans, H. Korsten, A.J.C. Ziel-Van Der Made, and et al. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer Int J Cancer 133 2013 335 345
26. J.C. Brase, M. Johannes, H. Mannsperger, and et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling BMC Cancer 11 2011 507
27. T. Nakagawa, T.M. Kollmeyer, B.W. Morlan, and et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy PLoS One 3 2008 e2318
28. M.D. Ruopp, N.J. Perkins, B.W. Whitcomb, and E.F. Schisterman Youden index and optimal cut-point estimated from observations affected by a lower limit of detection Biometrical J 50 2008 419 430
29. S. Minner, M. Enodien, H. Sirma, and et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 2011 5878 5888
30. C. Kumar-Sinha, S.A. Tomlins, and A.M. Chinnaiyan Recurrent gene fusions in prostate cancer Nat Rev Cancer 8 2008 497 511
31. K.L. Penney, J.A. Sinnott, K. Fall, and et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer J Clin Oncol 29 2011 2391 2396
32. M. Braun, D. Goltz, Z. Shaikhibrahim, and et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies Prostate Cancer Prostatic Dis 15 2012 165 169
33. K. Park, S.A. Tomlins, K.M. Mudaliar, and et al. Antibody-based detection of ERG rearrangement-positive prostate cancer Neoplasia 12 2010 590 598
34. S.A. Tomlins, N. Palanisamy, J. Siddiqui, A.M. Chinnaiyan, and L.P. Kunju Antibody-based detection of erg rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies Arch Pathol Lab Med 136 2013 935 946
35. A. Pettersson, R.E. Graff, S.R. Bauer, and et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Cancer Epidemiol Biomarkers Prev 21 2012 1497 1509
36. S. Smith, and S.A. Tomlins Prostate cancer subtyping biomarkers and outcome: is clarity emerging? Clin Cancer Res 20 2014 4733
37. R.J. Flavin, A. Pettersson, W.K. Hendrickson, and et al. SPINK1 protein expression and prostate cancer progression Clin Cancer Res 20 2014 4904
38. F. Khani, J.M. Mosquera, K. Park, and et al. Evidence for molecular differences in prostate cancer between African American and Caucasian Men Clin Cancer Res 20 2014 4925
39. D. Abdueva, M. Wing, B. Schaub, T. Triche, and E. Davicioni Quantitative expression profiling in formalin-fixed paraffin-embedded samples by Affymetrix microarrays J Mol Diagn 12 2010 409 417
40. G. Schaefer, J.-M. Mosquera, R. Ramoner, and et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer Prostate Cancer Prostatic Dis 16 2013 132 138
41. K.D. Berg, B. Vainer, F.B. Thomsen, and et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer Eur Urol 66 2014 861 862
42. G. Galletti, A. Matov, H. Beltran, and et al. ERG induces taxane resistance in castration-resistant prostate cancer Nat Commun 5 2014 5548
43. B. Ateeq, S.A. Tomlins, B. Laxman, and et al. Therapeutic targeting of SPINK1-positive prostate cancer Sci Transl Med 3 2011 72ra17
44. J.C. Brenner, B. Ateeq, Y. Li, and et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 2011 664 678
45. F.A. Shepherd, C. Domerg, P. Hainaut, and et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 2013 2173 2181
46. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253